Intech Investment Management LLC Reduces Stake in Merck & Co., Inc. $MRK

Intech Investment Management LLC lessened its stake in shares of Merck & Co., Inc. (NYSE:MRK) by 73.8% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 162,728 shares of the company’s stock after selling 459,082 shares during the quarter. Intech Investment Management LLC’s holdings in Merck & Co., Inc. were worth $17,129,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of MRK. Vanguard Group Inc. lifted its position in Merck & Co., Inc. by 0.9% in the fourth quarter. Vanguard Group Inc. now owns 254,322,763 shares of the company’s stock valued at $26,770,014,000 after acquiring an additional 2,185,853 shares during the last quarter. Geode Capital Management LLC boosted its stake in Merck & Co., Inc. by 0.4% in the fourth quarter. Geode Capital Management LLC now owns 60,047,984 shares of the company’s stock valued at $6,307,572,000 after acquiring an additional 249,110 shares in the last quarter. DLD Asset Management LP increased its position in shares of Merck & Co., Inc. by 30.1% during the third quarter. DLD Asset Management LP now owns 47,500,000 shares of the company’s stock worth $3,986,675,000 after purchasing an additional 11,000,000 shares in the last quarter. Fisher Asset Management LLC increased its position in shares of Merck & Co., Inc. by 3.3% during the fourth quarter. Fisher Asset Management LLC now owns 24,873,327 shares of the company’s stock worth $2,618,166,000 after purchasing an additional 805,201 shares in the last quarter. Finally, Legal & General Group Plc lifted its holdings in shares of Merck & Co., Inc. by 5.9% in the 3rd quarter. Legal & General Group Plc now owns 20,659,157 shares of the company’s stock valued at $1,733,923,000 after purchasing an additional 1,156,112 shares during the last quarter. Institutional investors and hedge funds own 76.07% of the company’s stock.

More Merck & Co., Inc. News

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck shareholders approved the company’s board nominees, executive pay package, and auditor ratification at its annual meeting, reinforcing governance continuity and removing a potential overhang. Merck Shareholders Back Board, Pay and Auditor Ratification
• Positive Sentiment: Merck announced participation in the Jefferies Global Healthcare Conference, which can spark investor attention if management provides updates on pipeline progress, guidance, or strategic priorities. Merck to Participate in the Jefferies Global Healthcare Conference
• Positive Sentiment: Merck’s chicken bronchitis vaccine was approved for use in China, expanding a potential animal-health opportunity in a large market and adding a modest growth catalyst. Merck chicken bronchitis vaccine approved for use in China
• Neutral Sentiment: Merck congratulated Ontario on expanding pharmacy scope rules, a policy development that is favorable for healthcare access but has no immediate direct financial impact on MRK. Merck Congratulates Ontario Government on Expanding Pharmacy Scope to Help Improve Access to Care
• Neutral Sentiment: Merck remained a heavily watched stock in Zacks coverage and on analyst/market screens, but those mentions were not tied to a new fundamental development. Here is What to Know Beyond Why Merck & Co., Inc. (MRK) is a Trending Stock
• Neutral Sentiment: The company’s upcoming Jefferies appearance and shareholder-call materials may keep attention on the stock, but they do not yet signal a clear change in earnings outlook. Merck & Co., Inc. (MRK) Shareholder/Analyst Call – Slideshow

Merck & Co., Inc. Stock Down 0.3%

MRK opened at $119.87 on Friday. The company has a debt-to-equity ratio of 1.02, a current ratio of 1.30 and a quick ratio of 1.06. The business has a 50 day simple moving average of $116.31 and a 200-day simple moving average of $111.41. The stock has a market capitalization of $296.05 billion, a P/E ratio of 33.77, a P/E/G ratio of 2.71 and a beta of 0.18. Merck & Co., Inc. has a 12 month low of $75.40 and a 12 month high of $125.14.

Merck & Co., Inc. (NYSE:MRK) last announced its quarterly earnings data on Thursday, April 30th. The company reported ($1.28) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.47) by $0.19. The firm had revenue of $16.29 billion for the quarter, compared to analyst estimates of $15.85 billion. Merck & Co., Inc. had a return on equity of 27.55% and a net margin of 13.59%.Merck & Co., Inc.’s quarterly revenue was up 4.9% on a year-over-year basis. During the same quarter in the prior year, the company posted $2.22 earnings per share. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. On average, equities analysts anticipate that Merck & Co., Inc. will post 5.16 earnings per share for the current fiscal year.

Merck & Co., Inc. Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, July 8th. Investors of record on Monday, June 15th will be issued a $0.85 dividend. The ex-dividend date is Monday, June 15th. This represents a $3.40 dividend on an annualized basis and a dividend yield of 2.8%. Merck & Co., Inc.’s dividend payout ratio is currently 95.77%.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on MRK shares. Guggenheim raised their price target on Merck & Co., Inc. from $122.00 to $140.00 and gave the stock a “buy” rating in a research note on Friday, February 6th. Barclays initiated coverage on Merck & Co., Inc. in a report on Friday, February 20th. They issued an “overweight” rating and a $140.00 price objective for the company. Zacks Research upgraded shares of Merck & Co., Inc. from a “strong sell” rating to a “hold” rating in a research report on Tuesday, March 17th. Weiss Ratings cut shares of Merck & Co., Inc. from a “hold (c+)” rating to a “hold (c)” rating in a research note on Friday, May 15th. Finally, JPMorgan Chase & Co. raised their price objective on shares of Merck & Co., Inc. from $125.00 to $135.00 and gave the stock an “overweight” rating in a research report on Monday, April 6th. One analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and seven have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $128.18.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.